Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab

Detalhes bibliográficos
Autor(a) principal: Magro, Fernando
Data de Publicação: 2019
Outros Autores: Lopes, Susana, Silva, Marco, Coelho, Rosa, Portela, Francisco, Branquinho, Diogo, Correia, Luís, Fernandes, Samuel, Cravo, Marília, Caldeira, Paulo, Sousa, Helena Tavares, Patita, Marta, Lago, Paula, Ramos, Jaime, Afonso, Joana, Redondo, Isabel, Machado, Patrícia, Philip, George, Lopes, Joanne, Carneiro, Fátima
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.1/12800
Resumo: Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab.
id RCAP_2760d3189de4e2a7d61c37ae4a5e7bf6
oai_identifier_str oai:sapientia.ualg.pt:10400.1/12800
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumabEndoscopic activityGolimumabHistological activitySerum soluble ST2Ulcerative colitisSuppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab.SAGE PublicationsSapientiaMagro, FernandoLopes, SusanaSilva, MarcoCoelho, RosaPortela, FranciscoBranquinho, DiogoCorreia, LuísFernandes, SamuelCravo, MaríliaCaldeira, PauloSousa, Helena TavaresPatita, MartaLago, PaulaRamos, JaimeAfonso, JoanaRedondo, IsabelMachado, PatríciaPhilip, GeorgeLopes, JoanneCarneiro, Fátima2019-10-08T13:03:01Z20192019-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/12800eng10.1177/1756284819869141info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-11-29T10:29:01Zoai:sapientia.ualg.pt:10400.1/12800Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-11-29T10:29:01Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
title Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
spellingShingle Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
Magro, Fernando
Endoscopic activity
Golimumab
Histological activity
Serum soluble ST2
Ulcerative colitis
title_short Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
title_full Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
title_fullStr Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
title_full_unstemmed Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
title_sort Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
author Magro, Fernando
author_facet Magro, Fernando
Lopes, Susana
Silva, Marco
Coelho, Rosa
Portela, Francisco
Branquinho, Diogo
Correia, Luís
Fernandes, Samuel
Cravo, Marília
Caldeira, Paulo
Sousa, Helena Tavares
Patita, Marta
Lago, Paula
Ramos, Jaime
Afonso, Joana
Redondo, Isabel
Machado, Patrícia
Philip, George
Lopes, Joanne
Carneiro, Fátima
author_role author
author2 Lopes, Susana
Silva, Marco
Coelho, Rosa
Portela, Francisco
Branquinho, Diogo
Correia, Luís
Fernandes, Samuel
Cravo, Marília
Caldeira, Paulo
Sousa, Helena Tavares
Patita, Marta
Lago, Paula
Ramos, Jaime
Afonso, Joana
Redondo, Isabel
Machado, Patrícia
Philip, George
Lopes, Joanne
Carneiro, Fátima
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Sapientia
dc.contributor.author.fl_str_mv Magro, Fernando
Lopes, Susana
Silva, Marco
Coelho, Rosa
Portela, Francisco
Branquinho, Diogo
Correia, Luís
Fernandes, Samuel
Cravo, Marília
Caldeira, Paulo
Sousa, Helena Tavares
Patita, Marta
Lago, Paula
Ramos, Jaime
Afonso, Joana
Redondo, Isabel
Machado, Patrícia
Philip, George
Lopes, Joanne
Carneiro, Fátima
dc.subject.por.fl_str_mv Endoscopic activity
Golimumab
Histological activity
Serum soluble ST2
Ulcerative colitis
topic Endoscopic activity
Golimumab
Histological activity
Serum soluble ST2
Ulcerative colitis
description Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab.
publishDate 2019
dc.date.none.fl_str_mv 2019-10-08T13:03:01Z
2019
2019-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.1/12800
url http://hdl.handle.net/10400.1/12800
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1177/1756284819869141
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817549711812329472

Registros relacionados